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ABSTRACT
Fatty liver disease is one of the main hepatic complications
associated with obesity. To date, there are no effective treatments
for this pathology apart from the use of classical fibrates. In this study,
we have characterized the in vivo effects of a novel conjugation of
oleic acid with an amphetamine derivative (OLHHA) in an animal
model of genetic obesity. Lean and obese Zucker rats received a daily
intraperitoneal administration of OLHHA (5 mg kg−1) for 15 days.
Plasma and liver samples were collected for the biochemical and
molecular biological analyses, including both immunohistochemical
and histological studies. The expression of key enzymes and proteins
that are involved in lipid metabolism and energy homeostasis was
evaluated in the liver samples. The potential of OLHHA to produce
adverse drug reactions or toxicity was also evaluated through the
monitoring of interactions with hERG channel and liver cytochrome.
We found that OLHHA is a drug with a safe pharmacological profile.
Treatment for 15 days with OLHHA reduced the liver fat content and
plasma triglyceride levels, and this was accompanied by a general
improvement in the profile of plasma parameters related to liver
damage in the obese rats. A decrease in fat accumulation in the liver
was confirmed using histological staining. Additionally, OLHHA was
observed to exert anti-apoptotic effects. This hepatoprotective activity
in obese rats was associated with an increase in the mRNA and
protein expression of the cannabinoid type 1 receptor and a decrease
in the expression of the lipogenic enzymes FAS and HMGCR
primarily. However, changes in the mRNA expression of certain
proteins were not associated with changes in the protein expression
(i.e. L-FABP and INSIG2). The present results demonstrate that
OLHHA is a potential anti-steatotic drug that ameliorates the obesity-
associated fatty liver and suggest the potential use of this new drug for
the treatment of non-alcoholic fatty liver disease.
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INTRODUCTION
Both alcoholic fatty liver (AFL) and non-alcoholic fatty liver
disease (NAFLD) are the result of an excessive fat accumulation in
the liver. Whereas AFL is associated with a long-term intake and
abuse of alcohol, the development of NAFLD is produced in the
absence of a history of excessive alcohol consumption.
Nonetheless, both AFL and NAFLD can progress to more severe
liver diseases, including steatohepatitis, fibrosis or cirrhosis.
NAFLD has consistently shown a dramatic increase in prevalence
over the last few decades in Western countries, reaching the 20-40%
prevalence rate and becoming an important health issue (Farrell and
Larter, 2006). Several studies have reported that NAFLD is closely
related to the metabolic syndrome (Bugianesi et al., 2005; Chavez-
Tapia et al., 2006) and is a risk factor associated with obesity, type II
diabetes mellitus, insulin resistance, hypertension and
hypertriglyceridemia (Marchesini et al., 2003). Given that the
pathogenesis of NAFLD is not yet fully elucidated, animal models
can provide an important complement to a better understanding
of this disease. As a result of the strong association between
obesity and NAFLD, animal models of obesity are suitable to
study the course and evolution of NAFLD. For instance, the obese
Zucker rat is a model of genetic obesity caused by a spontaneous
mutation in the leptin receptor that displays hyperphagia,
hyperinsulinemia, hypertriglyceridemia and development of fatty
liver in adulthood.
Although there are no pharmacological therapies for reversing
and preventing NAFLD, several synthetic and natural fatty acid-
derived molecules that have been identified as potential anti-obesity
drugs may represent an interesting pharmacological tool. These
lipid compounds act basically through two types of receptors related
to appetite regulation and/or energy homeostasis, the cannabinoid
type 1 receptor (CB1) and the peroxisome proliferator activated-
receptor α (PPAR-α).
Numerous studies suggest the involvement of CB1 activation in
the development of fatty liver associated with obesity. For instance,
a study using an in vitro model of steatosis has demonstrated a
downregulation of CB1 (De Gottardi et al., 2010). Other studies in
the liver have reported that the activation of CB1 increases the
expression of lipogenic genes and inhibits fatty acid oxidation,
whereas pretreatment with a CB1 antagonist prevents this effect
(Jourdan et al., 2010; Osei-Hyiaman et al., 2005, 2008). In fact, CB1
antagonists have shown hepatoprotective activity, and treatment
with rimonabant reverses and prevents the fatty liver in obeseReceived 13 January 2015; Accepted 27 July 2015
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Catalun ̃a (IQAC-CSIC), Barcelona, 08034 Spain.
*These authors contributed equally to this work
‡Authors for correspondence (fernando.rodriguez@ibima.eu;
antonia.serrano@ibima.eu)
This is an Open Access article distributed under the terms of the Creative Commons Attribution
License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution and reproduction in any medium provided that the original work is properly attributed.
1213
© 2015. Published by The Company of Biologists Ltd | Disease Models & Mechanisms (2015) 8, 1213-1225 doi:10.1242/dmm.019919
D
is
ea
se
M
o
d
el
s
&
M
ec
h
an
is
m
s
Zucker rats (Gary-Bobo et al., 2007) and reduces the liver fat in
abdominally obese subjects (Despres et al., 2009).
PPAR-α is involved in the control of multiple aspects of
energy balance, playing a pivotal role in the control of the
transcription of genes involved in lipid metabolism (Rosen,
2003). Among the several endogenous ligands proposed for
PPAR-α, N-oleoylethanolamine (OEA) acts as a lipid mediator of
satiety regulated by feeding (Rodríguez de Fonseca et al., 2001).
Besides inducing satiety, OEA is also involved in the control of
energy expenditure and fat utilization. In the liver, the PPARα-
mediated effects of OEA have been thoroughly investigated
(Thabuis et al., 2008). Previous studies have demonstrated that
OEA is able to prevent liver damage, reducing the hepatic lipid
content (Fu et al., 2005; Guzman et al., 2004; Serrano et al.,
2008b).
In this context, it has been described that a combinational therapy
with CB1 blockers and PPAR-α activators improves the individual
effect of each drug in obese Zucker rats, resulting in a decrease of
food intake, body weight gain and liver fat depots and an
improvement of liver function (Pavón et al., 2008; Serrano et al.,
2008a). Consequently, the development of new drugs with dual
activity as ligands for CB1 and PPAR-α has been reported in recent
years (Alvarado et al., 2008; Pérez-Fernández et al., 2011).
Recently, we have synthesized and characterized a series of
compounds derived from fatty acids conjugated with 3,4-
methylenedioxymethamphetamine metabolites as anti-obesity
drugs (Almeida et al., 2010). Among these novel molecules, the
N-[1-(3,4-dihydroxyphenyl)propan-2-yl]oleamide (OLHHA) has
inhibitory effects on feeding behaviour and produces antioxidant
effects, acting as a potent inhibitor of low-density lipoprotein
oxidation, as disclosed in the International Patent Application
No. WO 2011076966 A1 (De la Torre et al., 2011). Given that
OLHHA has been reported to have affinity for both the CB1 and
PPAR-α in the nanomolar range, these described effects may be
mediated by an interaction between CB1 and PPAR-α.
Considering that OLHHA represents a new pharmacological
approach to the treatment of obesity, this drug may be used
for related disorders, including NAFLD. To perform the
characterization of OLHHA, the present study is focused on
the toxicity and effects of treatment for 15 days with OLHHA
on the fatty liver of obese Zucker rats. Our results show that: (1)
OLHHA has a safe pharmacological profile and reduces both
plasma triglyceride levels and hepatic lipid accumulation in the
obese rats; (2) OLHHA induces changes in the mRNA and protein
expression of enzymes related to lipid metabolism in the liver; and
(3) OLHHA has an anti-apoptotic effect in the liver. These results
suggest that OLHHA may be a novel drug with a potential
therapeutic application for the treatment of NAFLD.
RESULTS
Effects of OLHHA on cytochrome P450 activity
We did not find any interference on fluorescence and quenching by
OLHHA. The IC50 value of this drug was higher than the values
exhibited by the control inhibitors (supplementarymaterial Table S1).
These results suggest that OLHHA might act as a moderate/
weak CYP inhibitor. Consequently, OLHHA is unlikely to induce
drug-drug interactions that might produce adverse reactions or
toxicity.
Effects of OLHHA on hERG
The IC50 value (>150 μM) of this drug was higher than the values of
the standard control inhibitors (IC50 value: amiodarone, 1.7 μM;
bepridil, 2.2 μM; haloperidol, 1.9 μM; terfenadine, 1.0 μM). Thus,
we did not observe any inhibitory activity of OLHHA on hERG,
which suggests that this drug displays a safety profile.
Effects of OLHHA on body weight and food intake
In the lean rats, OLHHA significantly reduced the body weight gain
(t14=3.22, **P=0.006; Fig. 1A). Regarding food intake, the results
of the two-way ANOVA showed a main effect of treatment
(F14,210=131.5, P<0.001) and a significant interaction between
treatment and time (F1,210=1.77, P=0.044; Fig. 1B). In fact, we
observed that treatment with OLHHA reduced the food intake, an
effect that was significant from the fifth day of treatment (*P<0.05,
fifth and sixth day; **P<0.01, seventh to 11th day and 15th day;
***P<0.001, 13th and 14th day).
In the obese rats, treatment with OLHHA produced no effect on
body weight gain (Fig. 1C), and although the two-way ANOVA
showed a significant main effect of treatment on cumulative food
intake (F14,210=29.45, P<0.001), the post hoc test comparisons
revealed no significant effects when compared with the vehicle-
treated rats (Fig. 1D).
TRANSLATIONAL IMPACT
Clinical issue
Non-alcoholic fatty liver disease (NAFLD) is a common disorder that is
caused by excessive fat accumulation in the liver in the absence of a
history of alcohol abuse. Although it has been considered as a benign
condition for a long time, it can progress to a more severe non-alcoholic
steatohepatitis or cirrhosis. Currently, there are no safe and effective
pharmacological therapies for NAFLD, and major efforts are being
dedicated to identification of new targets and strategies for reversing and
preventing NAFLD. Given that NAFLD is one of the consequences
associated with obesity, new anti-obesity drugs might represent an
interesting pharmacological tool. Substantial evidence suggests that the
blockade of the cannabinoid type 1 receptor (CB1) and/or the activation
of the peroxisome proliferator activated-receptor α (PPAR-α) have anti-
obesity effects and, therefore, might represent a feasible approach for
NAFLD treatment.
Results
In this study, the authors have shown that a novel conjugation of oleic
acid with an amphetamine derivative (OLHHA) is effective for the
treatment of NAFLD. This compound has been previously reported to
have affinity for both the CB1 and PPAR-α and it displays anti-obesity
properties. Chronic administration of OLHHA to obese Zucker rats
reduced both hepatic lipid accumulation and circulating triglyceride
levels. These animals also displayed a general improvement in the
profile of plasma parameters related to liver damage. This effect was
associated with an anti-apoptotic activity and with a downregulation of
the expression of enzymes involved in the biosynthesis of lipids in the
liver, thus reducing lipid production. In addition, toxicity studies revealed
that OLHHA is a drug with a safe pharmacological profile.
Implications and future directions
This study provides evidence that this novel anti-obesity drug has a
hepatoprotective effect and potent antioxidant properties, suggesting its
potential therapeutic application for the treatment of NAFLD. Although
OLHHA has been reported to have affinity for both the CB1 and the
PPAR-α, further studies are needed to establish the specific mechanism
of action of this drug. The safe pharmacological profile on the heart
human ether-à-go-go-related gene (hERG) channel (which is sensitive
to drug binding and can trigger a drug-induced long QT syndrome) and
liver cytochromes suggests this drug as a suitable candidate to progress
towards clinical trials for NAFLD.
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Effects of OLHHA and genotype on biochemical parameters
in the plasma
To characterize the metabolic state of OLHHA-treated rats, we
evaluated the levels of certain adipokines, indices of toxicity and
relevant parameters related to glucose and lipid metabolism in the
plasma (Table 1).
Parameters related to toxicity
The results of the two-way ANOVA showed that both genotype and
treatment had significant effects on biochemical parameters related
to toxicity in the plasma. Genotype produced significant effects
on all of the parameters evaluated [uric acid: F1,26=5.96, P=0.022;
urea: F1,26=16.51, P<0.001; creatinine: F1,26=48.72, P<0.001;
aspartate transaminase (AST): F1,26=47.86, P<0.001; alanine
transaminase (ALT): F1,26=60.96, P<0.001; γ-glutamyl
transpeptidase (GGt): F1,26=77.02, P<0.001], and the paired
comparisons revealed that the obese rats had increased levels of
creatinine (##P<0.01), AST (###P<0.001), ALT (##P<0.01) and
GGt (##P<0.01) compared with the vehicle-treated lean rats. In
addition to genotype, treatment had a main effect on urea
(F1,26=12.69, P=0.001), AST (F1,26=4.83, P=0.037) and ALT
concentrations (F1,26=12.73, P=0.001). Thus, OLHHA reduced
urea concentrations significantly (***P<0.001) in the obese rats
and ALT concentrations in both lean and obese rats (*P<0.05)
compared with their respective vehicle groups. Additionally, a
significant interaction between genotype and treatment was
observed (F1,26=9.38, P=0.005) and GGt (F1,26=7.40, P=0.012).
Adipokines
Both genotype (F1,26=261.7, P<0.001) and treatment (F1,23=5.21,
P=0.032) had significant effects on leptin levels. Although the
levels of leptin were increased in the plasma of the obese rats
(###P<0.001) compared with the vehicle-treated lean rats, OLHHA
reduced this increase in the obese rats (*P<0.05). The other
cytokines [i.e. interleukin-6 and tumor necrosis factor α (TNF-α)]
were not affected by genotype or treatment.
Parameters related to glucose metabolism
The ANOVA showed that treatment with OLHHA induced a
significant effect on glucose levels (F1,26=5.09, P=0.033), but
paired comparisons did not show significant differences among
subgroups. With regard to insulin levels, genotype had a main effect
Fig. 1. Effects of OLHHA on body weight, food
intake and hepatic fat in Zucker rats. Total
body weight gain (A,C), cumulative food intake
(B,D) and hepatic total fat (E) were evaluated in
the lean and obese rats after a 15-day exposure
to vehicle or OLHHA (5 mg kg−1, daily, i.p.). The
bars and points are the means±s.e.m. (n=8 rats
per group). The data were analyzed using two-
way ANOVA (treatment and time/genotype) and a
post hoc test for multiple comparisons. *P<0.05,
**P<0.01 and ***P<0.001 denote significant
differences compared with the vehicle-treated
rats. ###P<0.001 denotes significant difference
compared with the vehicle-treated lean rats.
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(F1,26=24.26, P<0.001), increasing the insulin concentrations
significantly in the obese rats (###P<0.001) compared with the
vehicle-treated lean rats. Although OLHHA caused an apparent
decrease in the insulin concentrations of the obese rats, it was not
significant.
Parameters related to lipid metabolism
With regard to the parameters related to cholesterol, genotype
had a significant main effect on total cholesterol (F1,26=175.5,
P<0.001) and high-density lipoprotein cholesterol concentrations
(F1,26=10.76, P=0.003). Indeed, the obese rats displayed higher
levels of both cholesterol (###P<0.001) and high-density lipoprotein
cholesterol concentrations (#P<0.05) than lean rats. However, there
was no effect of treatment on these molecules. Finally, the plasma
concentrations of triglycerides were significantly affected by
genotype (F1,28=49.80, P<0.001) and treatment (F1,28=4.31,
P=0.047). In addition, an interaction between both factors was also
detected (F1,28=4.26,P=0.048). The paired comparisons showed that
plasma triglyceride concentrations were increased in the obese rats
(###P<0.001) relative to the vehicle-treated lean rats. However,
treatment with OLHHA reduced significantly the increased
triglyceride concentrations (*P<0.05) in the obese rats.
Effects of OLHHA and genotype on fatty liver
Total fat content in the liver
Similar to plasma triglyceride concentrations, the total fat in the
liver was also affected by genotype (F1,28=85.16, P<0.001) and
treatment (F1,28=11.01, P=0.003), and there was an interaction
between genotype and treatment (F1,28=11.53, P=0.002). As shown
Fig. 1E, the obese rats displayed a significant increase in the total
hepatic fat content compared with lean animals (###P<0.001).
However, the treatment of the obese rats with OLHHA reduced the
fat content significantly (***P<0.001).
Histological analysis
Given that an increase in the hepatic fat accumulation was observed
in the obese rats, liver sections were evaluated using histological
staining with hematoxylin and eosin (Fig. 2A,B) and Oil Red O
(Fig. 2C,D). Consistent with the biochemical analysis, the
histological evaluation showed that treatment with OLHHA
improved the fatty liver in the obese rats, with a decrease in the
size of fat vacuoles but no change in the number of hepatocytes.
Immunohistochemical analysis of caspase-3
Complementary to the histological characterization of the liver, we
assessed apoptotic activity using immunohistochemistry of cleaved
(Fig. 2E) and total caspase-3 expression (Fig. 2F). Quantification of
the number of cleaved and total caspase-3-positive cells in the liver
sections revealed a significant decrease in the obese rats treated with
OLHHA (cleaved caspase-3: t4=3.36, *P=0.028; and total caspase-3:
t4=3.06, *P=0.038) relative to the vehicle-treated obese rats. It should
be clear that the vehicle-treated obese rats displayed an increased
caspase-3 activity compared with the lean rats (data not shown).
Therefore, the repeated treatment of obese rats with OLHHA
induced a decrease in the fat content of the fatty liver by decreasing
the size of fat vacuoles and by an anti-apoptotic activity.
Effects of OLHHA and genotype on CB1 and PPAR-α
expression in the liver
Given that OLHHA has been reported to have dual activity as a
ligand for CB1 and PPAR-α, we evaluated the expression of the
mRNA and the protein of both receptors in liver sections of lean
and obese rats. The mRNA expression of CB1 and PPAR-α was
affected by treatment in both genotypes. However, the protein
expression of these receptors was found to be affected in different
ways by treatment.
As shown in Fig. 3A, gene expression of CB1 was significantly
affected by treatment (F1,23=14.58, P=0.001), and OLHHA
treatment increased the mRNA levels of CB1 in both genotypes
(*P<0.05). Quantification of protein indicated a differential
effect of treatment in the lean rats (Fig. 3B) compared with the
obese rats (Fig. 3C). OLHHA induced a significant decrease in
the relative expression of CB1 in the lean rats (t10=2.36,
*P=0.038), whereas a significant increase was observed in the
obese rats (t10=3.12, *P=0.011) relative to the respective vehicle-
treated rats.
Table 1. Metabolic biochemical parameters in plasma of Zucker rats treated with OLHHA
Plasma biochemical parameters
Lean Zucker Obese Zucker
Vehicle OLHHA Vehicle OLHHA
Uric acid (mg dl−1) 0.68±0.04 0.65±0.02 0.71±0.03 0.80±0.05
Urea (mg dl−1) 34.50±1.16 34.00±1.31 33.50±0.53 26.88±0.84***
Creatinine (mg dl−1) 0.72±0.04 0.65±0.04 0.89±0.01## 0.89±0.02
AST (U l−1) 113.83±6.00 102.63±2.54 175.63±10.93### 151.63±8.64
ALT (U l−1) 46.83±1.25 34.25±3.99* 74.63±4.37## 61.88±2.71*
GGt (U l−1) 9.67±1.12 7.63±0.57 15.00±1.14## 17.75±0.60
Leptin (ng ml−1) 19.57±3.28 13.35±1.26 237.64±20.81### 188.39±10.05*
IL-6 (pg ml−1) 158.43±4.37 161.51±2.92 178.00±13.36 170.12±10.10
TNF-α (pg ml−1) n.d. 0.81±0.52 1.43±0.75 0.32±0.23
Glucose (mg dl−1) 151.83±19.56 196.50±14.11 173.00±5.42 192.63±16.22
Insulin (ng ml−1) 2.07±0.32 2.00±0.25 9.51±1.66### 6.22±0.79
Cholesterol (mg dl−1) 102.17±5.72 107.88±4.15 295.38±11.32### 269.75±21.28
HDL-C (mg dl−1) 26.33±1.76 28.88±0.96 35.00±2.24# 31.63±1.67
Triglycerides (mg dl−1) 111.50±25.19 110.88±10.14 573.88±70.87### 364.00±67.23*
Lean and obese Zucker rats were treated with vehicle or OLHHA (5 mg kg−1) daily for 15 days. Plasma parameters were analyzed 2 h after the last injection as
described in the Materials and Methods section. Values are expressed as the mean±s.e.m. (n=8 animals per group). Data were analyzed by two-way ANOVA
(genotype and treatment) for each parameter (see details in the Results section).
*P<0.05 and ***P<0.001 denote significant differences compared with the corresponding vehicle-treated group.
#P<0.05, ##P<0.01 and ###P<0.001 denote significant differences compared with the lean vehicle-treated group.
ALT, alanine transaminase; AST, aspartate transaminase; GGt, γ-glutamyl transpeptidase; HDL-C, high-density lipoprotein cholesterol; IL-6, interleukin-6;
n.d., not detectable; TNF-α, tumor necrosis factor α.
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Similar to CB1, genotype did not affect the mRNA expression of
PPAR-α (Fig. 3D), but treatment had a significant main effect
(F1,23=9.14, P=0.006). The post hoc test comparisons revealed a
significant inhibition of the expression in this nuclear receptor in the
lean rats (*P<0.05), which contrasts with that observed in the
mRNA levels of CB1. In this case, we did not find differences in the
Fig. 2. Effects of OLHHA on the fatty liver in obese Zucker rats. Representative images after the histological and immunohistochemical analysis of liver
sections. The histological analysis of liver sections was performed using Hematoxylin and Eosin (A,B) and Oil RedO stain (C,D) to examine the effects of OLHHA
on the size, number and appearance of hepatocytes and fat vacuoles in the obese rats. The immunohistochemical analysis of liver sections was performed
to detect cleaved caspase-3 (E) and total caspase-3 (F) to examine the apoptotic state after a 15-day exposure to vehicle or OLHHA (5 mg kg−1, daily, i.p.).
The scales are indicated in each image. The arrows indicate positive cells (brown stain). The bars indicate the means±s.e.m. (n=3 determinations in duplicate
per group). The data were analyzed using Student’s t-test. *P<0.05 denotes significant differences compared with the vehicle-treated rats.
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immunoblots for PPAR-α between OLHHA- and vehicle-treated
rats in both genotypes (Fig. 3E,F).
Effects of OLHHA and genotype on the mRNA expression of the
endocannabinoid system in the liver
Given that expression of CB1 was significantly affected and
that activation of CB1 is related to obesity-associated hepatic
steatosis, we analyzed the mRNA levels of enzymes involved in
the biosynthesis of endocannabinoids [diacylglicerol lipases
(DGLα and DGLβ) and N-acyl phosphatidylethanolamine
phospholipase D (NAPE-PLD)], degradative enzymes [fatty acid
amide hydrolase (FAAH) and monoacylglycerol lipase (MGL)]
and the cannabinoid type 2 receptor (CB2) (supplementary
material Fig. S1).
Focusing on the effects of OLHHA, the two-way ANOVA
revealed a significant main effect of treatment on the expression
of DGLα, DGLβ and MAGL (respectively: F1,23=5.51, P=0.028;
F1,23=5.13, P=0.034; and F1,23=7.751, P=0.011). The paired
comparisons detected a significant increase in the expression of
DGLα in the OLHHA-treated lean rats (*P<0.05) compared with
the vehicle group. In contrast, a significant decrease in the mRNA
expression of MGL was observed in the OLHHA-treated obese rats
(*P<0.05). Finally, although the analysis did not reveal any
significant main effect of treatment in the mRNA expression ofCB2,
a significant increase was observed in the OLHHA-treated lean rats
(*P<0.05) relative to the vehicle-treated rats.
Effects of OLHHA and genotype on the mRNA expression of
lipid metabolism in the liver
We selected certain enzymes implicated in the pathways of
biosynthesis of fatty acids [fatty acid synthase (FAS), acetyl-CoA
carboxylase (ACC) and stearoyl-CoA desaturase 1 (SCD-1)],
biosynthesis of cholesterol [3-hydroxy-3-methyl-glutaryl-CoA
reductase (HMGCR)], lipolysis [acyl-CoA oxidase (ACOX),
carnitine palmitoyl transferase 1 (CPT1) and lipoprotein lipase
(LPL)] or transport of fatty acids [liver-type fatty acid-binding
protein (L-FABP)].
Biosynthesis of fatty acids
The data revealed that the mRNA expression of FAS was affected
by genotype (F1,23=16.51, P=0.001) and treatment (F1,23=4.45,
P=0.047; Fig. 4A). Thus, FAS expression was significantly
increased in the obese rats (##P<0.01) compared with the lean
rats, but this increase in FAS was prevented in the OLHHA-treated
obese rats (*P<0.05). In contrast, the mRNA expression of ACC
was not affected by either genotype or treatment (Fig. 4B).
Regarding SCD-1 expression, we observed only a main effect of
genotype (F1,23=30.48, P<0.001), and the expression of SCD-1 was
Fig. 3. Effects of OLHHA on the mRNA and protein expression of CB1 and PPAR-α in the liver of Zucker rats. Relative mRNA levels and representative
immunoblots with relative protein expression of CB1 and PPAR-α were determined in the lean and obese rats after a 15-day exposure to vehicle or OLHHA
(5 mg kg−1, daily, i.p.). The mRNA expression of CB1 (A); and the immunoblots of CB1 and β-actin in both lean (B) and obese rats (C). The mRNA expression of
PPAR-α (D); and the immunoblots of PPAR-α and β-actin in both lean (E) and obese rats (F). The bars are the means±s.e.m. (n=6-8 determinations per group).
The data were analyzed using two-way ANOVA (treatment and genotype) and a post hoc test for multiple comparisons or Student’s t-test. *P<0.05 denotes
significant differences compared with the vehicle-treated rats.
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significantly increased in the obese rats (##P<0.01) relative to the
lean rats (Fig. 4C).
Biosynthesis of cholesterol
The analysis of the mRNA expression of HMGCR showed a
primary effect of treatment (F1,23=10.04, P=0.004), and OLHHA
reduced the expression of HMGCR, resulting in a significant
difference in the obese rats (*P<0.05; Fig. 4D).
Lipolysis
Treatment had a significant effect (F1,23=120.6, P<0.001) on ACOX
expression, and therewas a significant interaction between genotype
and treatment (F1,23=95.42, P<0.001), but not a main effect of
genotype (Fig. 4E). However, the post hoc test comparisons showed
that the expression of ACOXwas significantly increased in the obese
rats (###P<0.001) in comparison with the vehicle-treated lean rats.
Moreover, treatment with OLHHA increased the mRNA levels of
ACOX significantly in the lean rats (***P<0.001), with no changes
in the obese group. As shown in Fig. 4F, the CPT1 expression was
only affected by treatment (F1,23=6.75, P=0.016), but the decrease
observed in the obese rats was not significant after the paired
comparisons. The mRNA expression of LPL was significantly
affected by treatment (F1,23=5.65, P=0.027; Fig. 4G), but this effect
was only detected in the lean rats, with a significant increase in the
OLHHA-treated lean rats (*P<0.05).
Transport fatty acids
L-FABP was also analyzed (Fig. 4H), and the results indicated
significant effects of genotype (F1,23=5.87, P=0.024) and treatment
(F1,23=12.50, P=0.002) on the mRNA expression. The multiple
comparisons showed a significant increase in the OLHHA-treated
obese rats (*P<0.05) compared with the vehicle group.
Effects of OLHHA and genotype on transcription factors that
regulate lipid metabolism
The expression of the mRNA of the following regulatory factors
was analyzed by RT-qPCR: insulin-induced gene 1 and 2 (INSIG1
and INSIG2), sterol regulatory element-binding protein 1 and 2
(SREBP1 and SREBP2) and carbohydrate-responsive element-
binding protein (ChREBP).
Although treatment did not affect the mRNA expression of
INSIG1 (Fig. 5A), genotype had a main effect on the regulatory
factor (F1,23=7.61, P=0.012), resulting in a significant increase of
INSIG1 in the obese rats (#P<0.05). In contrast, INSIG2 expression
Fig. 4. Effects of OLHHA on themRNA of enzymes related to lipidmetabolism in the liver of Zucker rats.Relative mRNA levels of FAS (A), ACC (B), SCD-1
(C), HMGCR (D), ACOX (E), CPT1 (F), LPL (H) and L-FABP (I) were determined in the lean and obese rats after a 15-day exposure to vehicle or OLHHA
(5 mg kg−1, daily, i.p.). The bars are the means±s.e.m. (n=6-8 determinations per group). The data were analyzed using two-way ANOVA (treatment and
genotype) and a post hoc test for multiple comparisons. ##P<0.01 and ###P<0.001 denote significant differences compared with the vehicle-treated lean rats;
*P<0.05 and ***P<0.001 denote significant differences compared with the corresponding vehicle-treated group.
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was significantly affected by both genotype (F1,23=13.73, P=0.001)
and treatment (F1,23=75.61, P<0.001; Fig. 5B), with a significant
interaction of both factors (F1,23=22.38, P=0.001). Thus, OLHHA
produced a strong increase in the mRNA expression of INSIG2 in
both lean (***P<0.001) and obese rats (**P<0.01).
The ANOVA showed that the mRNA expression of SREBP1
(Fig. 5C) was affected by both genotype (F1,23=8.77, P=0.007) and
treatment (F1,23=5.34, P=0.030), with no interaction between these
factors. However, the SREBP2 expression was not affected by
genotype or treatment (Fig. 5D).
Regarding ChREBP, the mRNA expression was affected only
by genotype (F1,23=6.44, P=0.019; Fig. 5E), but the increase of
ChREBP in the obese rats was not significant after the post hoc test
comparisons with the lean rats.
Altogether, these data indicate that changes in the mRNA of FAS,
HMGCR, L-FABP and INSIG2 are detected in the obese rats.
Effects of OLHHA on the protein expression of enzymes and
transcription factors related to lipid metabolism in the liver
To address whether the alterations of mRNA expression observed in
obese rats treated with OLHHAwere associated with changes in the
protein expression, we analyzed the protein levels of enzymes and
regulatory factors affected by this drug in the obese rats primarily.
Fig. 6 illustrates representative immunoblots showing the protein
expression of FAS, HMGCR, L-FABP and INSIG2 in the liver of
obese rats. The obese rats treated with OLHHA displayed a
significant reduction in the protein expression of FAS (t11=2.34,
*P=0.042) and HMGCR (t10=2.96, *P=0.014) compared with
the vehicle-treated rats (Fig. 6A,B). However, the protein levels of
L-FABP and INSIG2 were not affected by treatment (Fig. 6C,D).
Additionally, we performed the same protein analysis in the lean rats
(supplementary material Fig. S2). The treatment of the lean rats with
OLHHA only had a significant effect on the protein expression of
FAS, resulting in a decrease (t10=2.59, *P=0.027).
Therefore, FAS and HMGCR are affected by OLHHA treatment,
with a significant decrease in the mRNA and protein expression in
the liver of obese rats.
DISCUSSION
Although repeated OLHHA treatment reduced the food intake and
body weight gain more clearly in the lean rats, we found that this
drug reduced the progression of NAFLD in the obese rats, with anti-
steatotic and hepatoprotective activity. Three relevant findings can
be highlighted from the present study regarding the obesity-
Fig. 5. Effects of OLHHA on the
mRNA expression of regulatory
factors related to lipid metabolism
in the liver of Zucker rats. Relative
mRNA levels of INSIG1 (A), INSIG2
(B), SREBP1 (C), SREBP2 (D) and
ChREBP (E) were determined in the
lean and obese rats after a 15-day
exposure to vehicle or OLHHA
(5 mg kg−1, daily, i.p.). The bars are
the means±s.e.m. (n=8
determinations per group). The data
were analyzed using two-way ANOVA
(treatment and genotype) and a post
hoc test for multiple comparisons.
#P<0.05 denotes significant
difference compared with the vehicle-
treated lean rats; **P<0.01 and
***P<0.001 denote significant
differences compared with the
corresponding vehicle-treated group.
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associated fatty liver. First, OLHHA treatment is a
pharmacologically safe drug that ameliorates the fatty liver
disease by decreasing the hepatic lipid content and circulating
triglycerides and improving the profile of toxicity parameters in the
plasma (e.g. transaminases ALT and AST). Second, the anti-
steatotic and hepatoprotective effects of OLHHA are confirmed by a
decrease in the size of hepatic fat vacuoles and anti-apoptotic
activity. Third, OLHHA treatment is associated with an increase in
the expression of CB1 and a downregulation in the expression of
the lipogenic enzymes in the liver of obese rats (FAS and HMGCR,
primarily).
Previously, we have reported that acute administration of
OLHHA significantly decreases food intake in food-deprived
Wistar rats (Almeida et al., 2010). In the present study, we
performed a repeated treatment of this dihydroxyphenyl derivative
in a genetic model of obesity and NAFLD, followed by initial assays
related to cardio- and hepatotoxicity. Thus, we showed that OLHHA
displayed a safe pharmacological profile because it did not interact
with the hERG cardiac potassium channels and it had no or
moderate effects on the activity of different isoforms of hepatic
cytochrome P450.
A 15-day treatment with an effective dose of OLHHA produced a
significant reduction in both food intake and body weight in the lean
Zucker rats, whereas it had no such effect in the obese animals. The
body weight reduction in the OLHHA-treated lean rats was
associated with the inhibitory effect on feeding behavior, because
we observed that the pair-fed rats displayed a similar reduction in
body weight compared with those receiving OLHHA (data not
shown). In contrast, OLHHA failed to inhibit body weight gain in
the obese Zucker rats, because the reduction of food intake was not
as evident as in the lean rats. Although plasma leptin was observed
to be improved after OLHHA treatment, the lack of effects on body
weight may be related to the malfunction of leptin signaling in the
obese Zucker rat. However, we observed an anti-steatotic and
hepatoprotective role of OLHHA in the obese rats with fatty liver or
NAFLD. We found that the repeated treatment with OLHHA
significantly decreased the fat depots in the fatty liver of obese rats
as well as lowering the triglyceride concentrations in plasma.
Regarding the analysis of biochemical parameters, the data
revealed strong differences in transaminases, cytokines and lipids in
the plasma of both rat genotypes treated with OLHHA. The
estimation of the plasma transaminase concentrations is a reliable
marker of hepatocellular damage, and these concentrations were
significantly higher in the obese than in the lean rats. However,
OLHHA treatment ameliorated the hepatic damage as indicated by
lower concentrations of transaminases (i.e. ALT). Similar effects
have been previously described for OEA and rimonabant in obese
Zucker rats (Gary-Bobo et al., 2007; Serrano et al., 2008a). TNF-α
Fig. 6. Effect of OLHHA on the protein expression of
relevant enzymes and factors related to lipid
metabolism in the liver of obese Zucker rats.
Representative immunoblots and relative protein
expression of FAS (A), HMGCR (B), L-FABP (C) and
INSIG2 (E) were determined in the obese rats after a
15-day exposure to vehicle or OLHHA (5 mg kg−1,
daily, i.p.). The bars are the means±s.e.m. (n=6
determinations per group). The data were analyzed
using Student’s t-test. *P<0.05 denotes significant
differences compared with the vehicle-treated group.
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is a pro-inflammatory cytokine involved in the development of
obesity-associated fatty liver, and its concentration is increased in
genetically obese rodents (Gary-Bobo et al., 2007; Xu et al., 2002).
Consistently, we also found that plasma concentrations of TNF-α
were higher in the obese than the lean rats. However, OLHHA
treatment induced a non-significant decrease in plasma TNF-α,
which has been previously described in obese Zucker rats treated
with rimonabant (Gary-Bobo et al., 2007).
These hepatoprotective effects were associated with a clear
histological improvement in liver steatosis, which was primarily
reflected in a decrease in the size of hepatic fat vacuoles but not in
the number of cells. The anti-steatotic role of OLHHA was
accompanied by anti-apoptotic effects in the liver. We observed
that the number of cells expressing cleaved and total caspase-3 was
significantly reduced in the liver of obese rats treated with OLHHA,
which is consistent with previous studies reporting that the
development and progression of NAFLD is associated with
activation of apoptosis pathways (Feldstein and Gores, 2005;
Guicciardi and Gores, 2005). Therefore, the reduction of lipid
content and cells immunoreactive for caspase-3 might contribute to
the hepatoprotective effect of OLHHA.
Similar effects have been previously reported with natural and
synthetic ligands for PPAR-α, such as OEA (Fu et al., 2005; Serrano
et al., 2008a) and the fibrates. However, although the fibrates
constitute the main clinical approach to treat hypertriglyceridemia,
the use of fibrates in NAFLD remains controversial. Whereas some
studies suggest a protective role of fenofibrate in hepatic steatosis,
others have reported no beneficial effects (for review, see
Kostapanos et al., 2013). These opposite effects may be explained
by the use of different models of NAFLD, such as dietary
manipulations, genetic obesity or hereditary fatty liver. Because
OLHHA has a wider pharmacological spectrum than the fibrates, the
reduction of hepatic fat content observed in the present study might
not be mediated exclusively by PPAR-α but derived from interaction
with other targets. In fact, we have detected no substantial changes in
both mRNA and protein expression of this nuclear receptor in the
obese rats. Nevertheless, we propose that the effects of OLHHA are
derived from an interaction between CB1 and PPAR-α. This is
supported by previous experimental observations that the treatment
of obese Zucker rats with either CB1 antagonist rimonabant (Gary-
Bobo et al., 2007) or the combined administration of rimonabant
with OEA (Serrano et al., 2008a) reduced fat depots in the liver and
circulating triglycerides. The present results show an increase in CB1
in Zucker rats treated with OLHHA, supporting the existence of
interactions between OLHHA and this cannabinoid receptor. This
upregulation was indeed observed in both mRNA and protein
expression in the obese rats, which has been suggested to be
associated with an increase in the efficacy of CB1 antagonists
(Kunos et al., 2008; Miller and Devi, 2011; Vickers et al., 2003).
These data support the suggestion that the biological activity of
OLHHA is similar to that of rimonabant. Regarding PPAR-α, we
found that OLHHA treatment induced a reduction of mRNA
expression, and this is a typical feature after chronic treatment with
an agonist, which confirms the existence of affinity of OLHHA for
these receptors. However, we detected no changes in the protein
expression using immunoblot.
To explore the molecular mechanisms underlying the anti-
steatotic role of the OLHHA, we investigated the expression of
key enzymes that are involved in lipid metabolism and energy
homeostasis in the liver. We observed that the mRNA expression of
lipogenesis-related enzymes was higher in the obese rats than in the
lean control animals. However, a repeated treatment with OLHHA
decreased the expression of mRNA and protein of both FAS and
HMGCR, enzymes involved in the biosynthesis of fatty acids and
cholesterol, respectively. Regarding other enzymes, mRNA
expression of INSIG2 and L-FABP was also modified in the obese
rats treated with OLHHA, but protein expression using immunoblot
analysis was not affected. INSIG2 is a negative regulator of the
cholesterol biosynthesis that binds to HMGCR, which leads to its
ubiquitylation and further degradation (Dong and Tang, 2010). In
agreement, the present results showed that the reduction in the
expression of HMGCR was associated with INSIG2 upregulation.
In contrast, OLHHA enhanced mRNA expression of L-FABP, a
protein involved in the uptake and intracellular transport of fatty
acids. The gene expression of L-FABP is regulated by PPAR-α, and
its expression has been reported to be upregulated by fibrates
(Brandes et al., 1990).
Together, these data suggest that the reduction in the hepatic and
circulating triglycerides observed after OLHHA treatment may be
associated with the downregulation of the expression of lipogenesis-
related enzymes in the fatty liver of obese rats. Similar to OLHHA, it
has been well documented that OEA reduces the serum triglyceride
concentrations as well as the lipid content in the liver of lean and
obese rat. However, although OEA exerts these effects through a
mechanism that involves PPAR-α, stimulating lipolysis and fatty
acid oxidation (Fu et al., 2005; Guzman et al., 2004), OLHHA
affects the lipid biosynthesis through a mechanism that differs from
those described for OEA because it involves cannabinoid signaling.
As commented previously, the CB1 might be also involved in the
mechanism of action of OLHHA. In this regard, the activation of
hepatic CB1 is associated with an increase of de novo fatty acid
synthesis, and this lipogenic response is abolished by CB1 blockade
(Osei-Hyiaman et al., 2005). Given that the endocannabinoid
system plays a main role in the regulation of energy homeostasis and
that it has also been reported that OLHHA has affinity for the CB1
(Almeida et al., 2010), we evaluated the gene expression of the
different components of this system in the liver of Zucker rats.
Consistent with previous reports showing that the endocannabinoid
system is altered in peripheral tissues in obese rats (Izzo et al., 2009,
2010), our results showed that this signaling system was
dysregulated in the liver. Regarding OLHHA, we observed a
strong increase in the gene expression of enzymes involved in
the metabolism of 2-arachidonoylglycerol (2-AG) as well as an
increase in both cannabinoid receptors.
In summary, our results show that OLHHA has an anti-steatotic
activity because it is able to reverse the obesity-associated fatty
liver (NAFLD) in an animal model of genetic obesity. This
hepatoprotective role is associated with the downregulation of
several lipogenesis-related enzymes in the liver. Although further
investigations are now required to establish the mechanism and
specific interactions of other pathways distinct to lipid metabolism
(e.g. glucose metabolism) that contribute to its in vivo effects,
OLHHA can be considered to represent a new class of drug with a
safe pharmacological profile that may have a potential clinical
application for the treatment of NAFLD.
MATERIALS AND METHODS
Animals and ethical statement
The experiments were performed on 8- to 9-week-old male Zucker rats
[obese ( fa/fa) and lean (+/?) rats] (Crl:ZUC-Leprfa; Charles River
Laboratories, Barcelona, Spain). The animals were housed individually
with a 12 h-12 h light-dark cycle (lights off 20.00 h) in a room with
temperature and humidity control. Water and rat chow pellets were available
ad libitum throughout the course of the present studies.
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All experimental procedures with animals were conducted in accordance
with the European Community Directive 2010/63/EU and Spanish
Legislation (Real Decreto 53/2013, BOE 34/11370-11421, 2013)
regulating the care and use of laboratory animals. All efforts were made
to minimize animal suffering, and the protocols were approved by the Ethics
Committee for Animal Experiments of the Universidad de Malaga. All
studies involving animals are reported in accordance with the ARRIVE
guidelines for reporting experiments involving animals (Kilkenny et al.,
2010; McGrath et al., 2010).
Drugs
N-[1-(3,4-dihydroxyphenyl)propan-2-yl]oleamide (OLHHA) was
synthesized as previously described (Almeida et al., 2010). OLHHA was
dissolved in a vehicle containing 5% Tween 80 in saline and injected
intraperitoneally (i.p.) at a dose of 5 mg per kg body weight (mg kg−1).
Human cytochrome P450 (CYP) fluorometric inhibition assay
The assay was performed in collaboration with the Fundacion Medina
(Centro de Excelencia en Investigacion de Medicamentos Innovadores en
Andalucia, Granada, Spain). OLHHA and control inhibitors (ketoconazole,
sulphafenazole and quinidine) were serially diluted by using a dilution
factor of 2:1 to provide different concentrations. Dimethyl sulfoxide
(0.35%) and acetonitrile (0.65%) were used as organic solvents, with a
maximal concentration in the assay established as 105 μM. Both
fluorescence and quenching interferences were determined for each
compound in triplicate. Therefore, IC50 values were obtained in
fluorometric CYP inhibition assays with three different CYPs: CYP3A4,
CYP2C9 and CYP2D6.
Human ether-à-go-go related gene (hERG) channel assay using a
cell fluorescence functional assay
This study was performed in collaboration with the above-mentioned
institution. HEK-293 (human embryonic kidney) cells expressing hERG K+
channels were seeded into poly-D-lysine-coated 96-well plates. The FluxOR
potassium channel assay was performed as outlined in the product
information sheet (available from Invitrogen, Carlsbad, CA, USA), and
measured at room temperature via the FLIPR Tetra System (Molecular
Devices, Sunnyvale, CA, USA). After 24 h of incubation, the plates were
washed with assay buffer of the following composition (mM): 165 NaCl, 4.5
KCl, 2 CaCl2, 1 MgCl2, 10 HEPES and 10 glucose, pH 7.4. Next, loading
buffer containing the FluxOR dye mix was added into each well, and the
cells were incubated for 1 h at room temperature. They were washed once in
assay buffer and then incubated with the same buffer containing OLHHA
and control inhibitors (amiodarone, bepridil, haloperidol and terfenadin) at a
dilution of 1:200, on the EP3 pipetting platform. Subsequently, compounds
and OLHHAwere measured in triplicate in each of three independent plates
seeded with hERG-expressing HEK-293 cells, using 12-point curves (1:2
dilutions, and 150 mM as maximal concentration). Astemizol (1 mM) was
added to each well as the positive control, whereas 0.5% DMSO was used
as negative control. Next, plates containing both control inhibitors and
OLHHA were allowed to equilibrate for 30 min at room temperature.
Finally, stimulation buffer (Tl2SO4+K2SO4) was added to the plates via
FLIPR Tetra System for kinetic analysis during 120 s, and IC50 values were
obtained.
A 15-day study of feeding behavior in Zucker rats treated with
OLHHA
Animals received a daily i.p. injection of vehicle or OLHHA (5 mg kg−1)
for 15 consecutive days. Eight rats per group were used for the experiment.
Food intake (in grams per kilogram of body weight) and body weight (in
grams) were measured daily.
Sample collection
The rats were killed 2 h after the last dose. OLHHA-treated and control
animals were anesthetized with sodium pentobarbital (50 mg kg−1, i.p.),
and blood and liver samples were collected. Blood was centrifuged (2100 g
for 8 min, 4°C) and the plasma kept for further analysis. Liver samples were
divided into two pieces: one piece was snap-frozen in liquid N2 and stored at
−80°C until analysis; and the other piece was fixed in 4% paraformaldehyde
in 0.1 M phosphate-buffered saline (PBS) by immersion for 24 h and
embedded in paraffin for histological and immunohistochemical analysis.
Biochemical analysis in plasma
The following metabolites, metabolic hormones and adipokines were
measured in plasma: uric acid, urea, creatinine, aspartate transaminase
(AST), alanine transaminase (ALT), γ-glutamyl transpeptidase (GGt),
leptin, interleukin-6, tumor necrosis factor α (TNF-α), glucose, insulin,
cholesterol, high-density lipoprotein cholesterol and triglycerides.
The metabolites were analyzed using commercial kits according to the
manufacturer’s instructions in a Hitachi 737 Automatic Analyzer (Hitachi,
Tokyo, Japan). The levels of leptin, IL-6 and TNF-α were measured using
commercial rat enzyme-linked immunosorbent assay kits (Abcam,
Cambridge, UK). The plasma levels of insulin were measured using a
commercial rat insulin enzyme-linked immunosorbent assay kit (Mercodia,
Uppsala, Sweden).
Liver fat extraction
Total lipids were extracted from frozen liver samples with chloroform-
methanol (2:1, v/v) according to the method of Bligh and Dyer (1959). After
two centrifugation steps (2800 g for 10 min, 4°C), the lower phase,
containing lipids, was extracted. N2 was used to dry each sample, and the
liver fat content was determined by subtracting the weight of the empty tube
from the weight of the tube containing the total fat extraction. The data were
expressed as a percentage of tissue weight.
Histological evaluation
Liver samples embedded in paraffin were cut by microtome (5 μm thick),
mounted on D-polylysinated glass slides, deparaffinized in xylene, and
stained with hematoxylin and eosin. In addition to hematoxylin and eosin
stain, cryostat frozen sections were stained with Oil Red O for analysis of
lipids and fat depots in the liver.
Immunohistochemical analysis
Liver samples embedded in paraffin were cut into 5-μm-thick sections using
a Microm HM325 microtome (MICROM, Walldorf, Germany) and
organized on glass slides. The sections were dewaxed, washed several
times with Tris-buffered saline (TBS, pH 7.8), and incubated in 3%
hydrogen peroxide in TBS for 20 min in the dark at room temperature in
order to inactivate endogenous peroxidase. After three washes in PBS for
5 min, antigen retrieval was achieved by incubating in sodium citrate (pH
6.0) for 20 min at 80°C. A background blocker solution containing 10%
donkey serum, 0.3% Triton X-100 and 0.1% sodium azide was used
to incubate the sections for 1 h, which was followed by 48 h of incubation at
4°C with the primary antibody rabbit anti-cleaved caspase-3 (Novus
Biologicals, Abingdon, UK) at a dilution of 1:100. Then, the sections were
washed three times with TBS, incubated in a biotinylated donkey anti-rabbit
IgG (Amersham, GE Healthcare Europe, Barcelona, Spain) diluted 1:500
for 90 min, washed again in TBS, and incubated in ExtrAvidin peroxidase
(Sigma, St Louis, MO, USA) diluted 1:2000 in darkness at room
temperature for 1 h. After three washes in TBS in darkness, we revealed
immunolabeling with 0.05% diaminobenzidine (DAB; Sigma), 0.05%
nickel ammonium sulfate and 0.03% H2O2 in PBS. All steps were
performed through gentle agitation at room temperature. The sections were
counterstained with hematoxylin. Then, they were dehydrated in ethanol,
cleared in xylene and coverslipped with Eukitt mounting medium
(O. Kindler, Freiburg, Germany).
Digital high-resolution photomicrographs of the liver tissue were taken
with a 40× objective in the same conditions of light and brightness/contrast
using an Olympus BX41 microscope equipped with an Olympus DP70
digital camera (Olympus Iberia SAU, Barcelona, Spain). Quantification of
the number of cleaved/total caspase-3-positive cells was performed using
random areas (1 mm2) from replicates and samples (two replicates per
sample, three samples per group) using the analysis software ImageJ 1.38x
(National Institutes of Health, Bethesda, MA, USA).
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RNA isolation and RT-qPCR analysis
Total RNA was extracted from liver samples using Trizol Reagent (Gibco
BRL Life Technologies, Baltimore, MD, USA). The total mRNA
concentrations were quantified using a spectrophotometer to ensure ratios
of absorbance at 260 to 280 nm of 1.8-2.0.
The reverse transcription was performed using the Transcriptor Reverse
Transcriptase kit and random hexamer primers (Transcriptor RT; Roche
Diagnostic, Mannheim, Germany). The quantitative real-time reverse
transcription polymerase chain reaction (RT-qPCR) was performed using
an ABI PRISM® 7300 Real-Time PCR System (Applied Biosystems, Foster
City, CA, USA) and the FAM dye label format for the TaqMan Gene
Expression Assays (Applied Biosystems). The absolute values from each
sample were normalized relative to the housekeeping β-actin gene (Actb).
The relative quantification was calculated using the ΔΔCt method and
normalized to the control group. Primers for the RT-qPCR (supplementary
material Table S2) were obtained based on the Applied Biosystems genome
database of rat mRNA references (http://bioinfo.appliedbiosystems.com/
genome-database/gene-expression.html).
Protein extraction and immunoblot analysis
The liver samples were disrupted in lysis buffer supplemented with a
cocktail of protease inhibitors (cOmplete Tablets; Roche Diagnostic,
Mannheim, Germany). The suspension was shaken for 2 h at 4°C and
centrifuged at 20,800 g for 15 min at 4°C, recovering the soluble fraction
below the fat ring. Protein concentration was determined by Bradford
protein assay. The extracts of protein were diluted 1:1 in 2× sample buffer
containing dithiothreitol and boiled for 5 min before submitting to SDS-
PAGE. Samples (50 µg of total proteins each) were resolved in gradient
SDS-PAGE gels (Bio-Rad Laboratories, Madrid, Spain) and blotted onto
nitrocellulose membranes (Bio-Rad Laboratories). The membranes were
blocked in TBS-T (50 mM Tris-HCl, pH 7.6; 200 mM NaCl and 0.1%
Tween-20) with 2% bovine serum albumin for 1 h. Specific proteins were
detected through incubation in TBS-T containing 2% bovine serum albumin
for 2 h with the corresponding primary antibodies: rabbit anti-FAS (Cell
Signaling Technology, Danvers, MA, USA), anti-HMGCR (Abcam), anti-
PPARα (Fitzgerald, Acton, MA, USA), anti-CB1 (Abcam), anti-INSIG2
(Santa Cruz Biotechnology, Heidelberg, Germany), anti-LFABP (Santa
Cruz Biotechnology) and anti-actin (Sigma).
After extensive washing in TBS-T, anti-rabbit horseradish-peroxidase-
conjugated secondary antibody (Promega, Madison, MI, USA) was added
for 1 h. The membranes were subjected to extensive washings in TBS-T,
and the specific protein bands were revealed using the enhanced
chemiluminescence detection system (Santa Cruz Biotechnology, Dallas,
TX, USA), in accordance with the manufacturer’s instructions, and the
images were visualized in an Autochemi-UVP Bioimaging System. Bands
were quantified using a densitometric analysis through ImageJ software
(Wayne S. Rasband, ImageJ; US National Institutes of Health, Bethesda,
MA, USA; http://imagej.nih.gov/ij, 1997–2012). The values were expressed
in relation to β-actin.
Statistical analysis
All the data in the graphs and tables are expressed as the means±s.e.m.
The statistical analysis was performed using GraphPad Prism version 5.04
(GraphPad Software, San Diego, CA, USA). The significance of differences
within and between groups was primarily evaluated using two-way analysis
of variance [ANOVA; factors: treatment (vehicle/OLHHA) and genotype
(obese/lean) or treatment and time] and the appropriate post hoc test for
multiple comparisons. The analysis of two groups was performed using
Student’s unpaired t-test. A P-value of less than 0.05 was considered
significant.
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Alvarado, M., Goya, P., Macıás-González, M., Pavón, F. J., Serrano, A.,
Jagerovic, N., Elguero, J., Gutiérrez-Rodrıǵuez, A., Garcıá-Granda, S.,
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